A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer
- 17 November 2005
- journal article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 15 (6) , 1023-1034
- https://doi.org/10.1111/j.1525-1438.2005.00483.x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian CancerJournal of Clinical Oncology, 2004
- CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patientsGynecologic Oncology, 2004
- Monitoring of immune responses to CA125 with an IFN-γ ELISPOT assayJournal of Immunological Methods, 2003
- Inducing Tumor Immunity through the Selective Engagement of Activating Fcγ Receptors on Dendritic CellsThe Journal of Experimental Medicine, 2002
- Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based VaccinesJournal of Clinical Oncology, 2002
- Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic CellsThe Journal of Experimental Medicine, 2002
- Induction of CA125-Specific B and T Cell Responses in Patients Injected with MAb-B43.13—Evidence for Antibody-Mediated Antigen-Processing and Presentation of CA125 in VivoCancer Biotherapy & Radiopharmaceuticals, 2001
- Lack of Efficacy of 24-h Infusional Topotecan in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group TrialGynecologic Oncology, 1999
- Clinical Course of Ovarian Cancer Patients Under Repeated Stimulation of HAMA Using MAb OC125 and B43.13Hybridoma, 1993
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983